Urturn Secures $13.4 Mln in Series A Funding
Urturn, a social platform, said on Wednesday that it has completed Series A funding of $13.4 million. The fundraising round included a $10.7 million investment by Balderton Capital, a European venture capital firm, and a $2.7 million investment from the private equity division of Debiopharm Group, a Swiss-based global pharmaceutical company. And as part of the agreement, Balderton's founding partner Barry Maloney will join Urturn's board.
22 May 2013•5 mins read
